
Crossject S.A (ALCJ) | Financial Analysis & Statements
Crossject S.A. | Small-cap | Healthcare
Crossject S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
31.6M
Total Liabilities
34.2M
Shareholders Equity
-2.7M
Cash Flow Metrics
Revenue & Profitability Trend
Crossject S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 145.0K | 954.0K | 912.0K | 0 |
Cost of Goods Sold | 9.2M | 6.3M | 2.2M | 1.3M | 563.0K |
Gross Profit | -9.2M | -6.1M | -1.2M | -390.0K | -563.0K |
Gross Margin % | 0.0% | -4,231.0% | -126.4% | -42.8% | 0.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 569.0K | -188.0K | 1.3M | 969.0K | 956.0K |
Total Operating Expenses | 569.0K | -188.0K | 1.3M | 969.0K | 956.0K |
Operating Income | -13.0M | -11.8M | -13.3M | -11.8M | -10.6M |
Operating Margin % | 0.0% | -8,138.6% | -1,392.9% | -1,296.4% | 0.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | 19.0K | 42.0K |
Interest Expense | - | - | - | 845.0K | 408.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -15.6M | -11.5M | -13.4M | -12.6M | -11.5M |
Income Tax | -2.8M | -2.9M | -2.2M | -1.8M | -1.6M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -12.8M | -8.6M | -11.2M | -10.8M | -9.8M |
Net Margin % | 0.0% | -5,958.6% | -1,169.5% | -1,184.9% | 0.0% |
Key Metrics | |||||
EBITDA | -6.5M | -8.1M | -7.4M | -6.8M | -5.6M |
EPS (Basic) | - | €-0.23 | €-0.30 | €-0.41 | €-0.40 |
EPS (Diluted) | - | €-0.23 | €-0.30 | €-0.41 | €-0.40 |
Basic Shares Outstanding | - | 36950933 | 36840307 | 26272917 | 24245223 |
Diluted Shares Outstanding | - | 36950933 | 36840307 | 26272917 | 24245223 |
Income Statement Trend
Crossject S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 7.0M | 2.3M | 7.8M | 10.0M | 8.1M |
Short-term Investments | - | - | - | 154.0K | 144.0K |
Accounts Receivable | - | 4.8M | 3.5M | 2.0M | 0 |
Inventory | 3.4M | 3.1M | 2.0M | 1.4M | 1.5M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 15.9M | 10.7M | 13.8M | 14.4M | 18.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.1M | 10.6M | 5.2M | 6.1M | 6.9M |
Goodwill | 9.6M | 10.7M | 10.7M | 9.1M | 7.5M |
Intangible Assets | 9.6M | 10.7M | 10.7M | 9.1M | 7.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | 2.0K |
Total Non-Current Assets | 15.7M | 18.0M | 19.0M | 17.1M | 14.9M |
Total Assets | 31.6M | 28.6M | 32.9M | 31.5M | 33.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.6M | 4.3M | 3.5M | 2.0M | 2.4M |
Short-term Debt | - | - | - | - | 5.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 8.0K | 66.0K | 12.0K |
Total Current Liabilities | 6.9M | 6.5M | 5.3M | 3.1M | 3.6M |
Non-Current Liabilities | |||||
Long-term Debt | 18.4M | 18.9M | 14.1M | 25.6M | 24.3M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 8.1M | 7.2M | 9.3M | 7.5M | -1.0K |
Total Non-Current Liabilities | 27.4M | 27.4M | 24.8M | 33.9M | 31.1M |
Total Liabilities | 34.2M | 33.9M | 30.2M | 37.0M | 34.7M |
Equity | |||||
Common Stock | 4.6M | 3.7M | 3.7M | 2.6M | 2.4M |
Retained Earnings | -15.4M | -10.4M | -19.9M | -14.8M | -10.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -2.7M | -5.3M | 2.7M | -5.5M | -1.1M |
Key Metrics | |||||
Total Debt | 18.4M | 18.9M | 14.1M | 25.6M | 29.7M |
Working Capital | 9.0M | 4.2M | 8.5M | 11.3M | 15.1M |
Balance Sheet Composition
Crossject S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -12.8M | -8.6M | -11.2M | -10.8M | -9.8M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
Operating Cash Flow | -13.1M | -8.7M | -11.2M | -10.8M | -9.9M |
Investing Activities | |||||
Capital Expenditures | -3.4M | -2.6M | -6.8M | -6.7M | -6.1M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -3.4M | -2.6M | -6.8M | -6.7M | -6.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 5.5M | 8.1M | 4.1M | 20.9M | 11.9M |
Debt Repayment | -3.3M | -5.1M | -1.5M | -7.1M | -215.0K |
Financing Cash Flow | 16.1M | 3.4M | 9.6M | 14.5M | 11.9M |
Free Cash Flow | -11.5M | -12.6M | -11.9M | -12.8M | -11.6M |
Net Change in Cash | -372.0K | -7.9M | -8.3M | -3.0M | -4.0M |
Cash Flow Trend
Crossject S.A Key Financial Ratios
Valuation Ratios
Forward P/E
7.65
Price to Sales
20.76
PEG Ratio
7.65
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-246.47%
Return on Equity
478.68%
Return on Assets
-26.91%
Financial Health
Current Ratio
1.66
Debt to Equity
-7.88
Beta
0.84
Per Share Data
EPS (TTM)
€-0.28
Book Value per Share
€-0.06
Revenue per Share
€0.09
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alcj | 85.4M | - | - | 478.68% | 0.00% | -7.88 |
EssilorLuxottica | 123.5B | 51.90 | 3.26 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.3B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
Visiomed Group SA | 53.2M | 57.80 | 2.10 | 3.68% | 6.58% | 32.03 |
Bonyf N.V | 7.8M | - | 17.50 | -1.38% | 8.02% | 0.00 |
Spineway S.A | 4.5M | 0.02 | 0.18 | -8.42% | -16.10% | 6.46 |
Financial data is updated regularly. All figures are in the company's reporting currency.